Frankfurt - Delayed Quote EUR
Zai Lab Limited (1ZL.F)
25.60
+0.60
+(2.40%)
As of 8:08:28 AM GMT+2. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 16 | 16 |
| Avg. Estimate | 127.57M | 152.21M | 564.5M | 842.58M |
| Low Estimate | 124.5M | 147.98M | 551M | 715M |
| High Estimate | 129.9M | 156.09M | 590.8M | 951M |
| Year Ago Sales | 100.5M | 102.27M | 398.99M | 564.5M |
| Sales Growth (year/est) | 26.93% | 48.84% | 41.48% | 49.26% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| 1ZL.F | -- | -- | -- | -- |
| S&P 500 | 12.66% | 3.22% | 7.99% | 13.82% |
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 3/27/2025 |
| Maintains | JP Morgan: Overweight to Overweight | 3/13/2025 |
| Initiated | Scotiabank: Sector Outperform | 3/7/2025 |
| Downgrade | B of A Securities: Buy to Neutral | 3/3/2025 |
| Reiterates | Cantor Fitzgerald: Overweight | 10/25/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 10/21/2024 |